Emyria Limited (ASX: EMD) - Share Price

Current share price for EMD : $0.039 0.002 (4.88%)⁺

Emyria Limited (EMD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in delivering and developing new treatments for mental health and selected neurological conditions. The Group's activities are informed by Real-World Data collected with patients across its wholly owned clinical service subsidiaries.

EMD General Information ⁺

ASX Code	EMD
Website	N/A
Industry/Sector	Pharmaceuticals
Market Cap ($M)	31
EMD Share Price	$0.039
Day High	$0.042
Day Low	$0.039
Last Close	$0.041
EMD Share Price Movement	$0.00 ( 4.88% )

Prices as at 16:40, 29 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Emyria Limited (EMD) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Emyria Limited (EMD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Emyria Limited (EMD) price-sensitive announcements

EMD - September 2026 Quarterly Activities Report and Appendix 4C

Emyria Limited’s September 2026 Quarterly Activities Report and Appendix 4C reported a str

Emyria Limited (EMD)
29 Oct 2026 | 9:50 AM

EMD - Emyria Successfully Opens First NSW Empax Clinic

Emyria Limited announced that it has successfully opened its first New South Wales Empax c

Emyria Limited (EMD)
29 Sep 2026 | 9:03 AM

EMD - FDA Selects EMD to Present at Psychedelic Medicines Hearing

Emyria Limited announced that it has been selected by the U.S. Food and Drug Administratio

Emyria Limited (EMD)
10 Sep 2026 | 9:35 AM

EMD - Emyria Set to Launch First NSW Clinic

Emyria Limited announced that its first Sydney clinic is on track to open in September 202

Emyria Limited (EMD)
8 Sep 2026 | 8:23 AM

Emyria Limited (EMD) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	September 2026 Quarterly Activities Report and Appendix 4C	29 Oct 2026 9:50AM	$0.041	$0.039	fallen by 4.88%
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	Annual Report	9 Oct 2026 11:40AM	$0.041	$0.039	fallen by 4.88%
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	Appendix 4G and Corporate Governance Statement	9 Oct 2026 11:37AM	$0.041	$0.039	fallen by 4.88%
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	Letter to Shareholders - Notice of Annual General Meeting	9 Oct 2026 11:35AM	$0.041	$0.039	fallen by 4.88%
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	Notice of Annual General Meeting/Proxy Form	9 Oct 2026 11:34AM	$0.041	$0.039	fallen by 4.88%
Emyria Limited (EMD) ORDINARY FULLY PAID	Health Care	$31	Retirement of Non-Executive Director	9 Oct 2026 11:31AM	$0.041	$0.039	fallen by 4.88%

EMD Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$5.88	-$0.80	14.30%	0.00%	0.0%
2025A	-$3.15	-$0.70	-44.90%	0.00%	0.0%
2024A	-$4.56	-$1.30	-28.30%	0.00%	0.0%

EMD Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Clarity Pharmaceuticals Ltd (CU6)	$584M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Emyria Limited (EMD)	$33M	0.1429	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,402M	-0.7857	0.2462	0.9655	81.4353	65.3448	33.2456	0.00%	1.74%	2.06%

EMD Directors

Name	Position	Start Date
Dr Michael Winlo	Managing Director	8 Nov 2019
Mr Greg Hutchinson	Non-Executive Chairman, Non-Executive Director	21 Nov 2023
Sir John Tooke	Non-Executive Director	10 Feb 2020
Dr Karen Smith	Non-Executive Director	29 Nov 2021
Dr Mohit Kaushal	Non-Executive Director	21 Aug 2023

Emyria Limited (EMD) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
29 Aug 2025	HUTCHINSON, Greg	Issued	Indirect Shares	7,583,333	$0.024	$181,999.992
29 Aug 2025	WINLO, Michael	Issued	Direct Shares	208,333	$0.024	$4,999.992
4 Apr 2025	WINLO, Michael	Buy	Direct Shares	69,378	$0.027	$1,873.206

See all changes in directors' interest & trades for Emyria Limited (EMD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

EMD Management

Name	Position
Sir John Tooke	Chair of Clinical Advisory
Mary Ann Rennie	Chief Operating Officer
Susan Patricia Park	Company Secretary
Claudia Sullivan	Head of Clinical Governance
Tatjana Heinrich	Head of Preclinical Drug Development
Claire Kullack	Lead Therapist
Clare Kullack	Lead Therapist
Matt Piggot	Leads Emyria's Medicinal Chemistry Program
Jon Laugharne	Medical Director/Lead Psychiatrist
Adrienne Smith	Project Manager

EMD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Emyria Limited (EMD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
54,788,694 (8.25%)	Mal Washer Nominees Pty Ltd
35,071,429 (7.14%)	Gregory Hutchinson
19,655,556 (5.47%)	Mercator Shipwrights Pty Ltd

EMD Calendar of Events

Date	Event
08 October 2027	Report (Annual)
30 August 2027	Report (Prelim)
25 February 2027	Report (Interim)
12 November 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us